Preparation and in vitro evaluation of 111In-CHX-A″-DTPA- labeled anti-VEGF monoclonal antibody bevacizumab

Human Antibodies

Volumn 19, Issue 4, 2010, Pages 107-111

  Hosseinimehr, Seyed Jalal ^a,b   Orlova And, Anna ^a   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

avastin; Bevacizumab; indium; scintigraphy; VEGF

Indexed keywords

BEVACIZUMAB; INDIUM 111; N [2 AMINO 3 (4 AMINOPHENYL)PROPYL]CYCLOHEXANE 1,2 DIAMINE N,N,N,N,N PENTAACETIC ACID BEVACIZUMAB IN 111; PENTETIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG CONJUGATION; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; EVALUATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLON; FEMALE; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; ISOTHIOCYANATES; MALE; MICE; OVARY; PENTETIC ACID; PROSTATE; RADIOIMMUNODETECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650604110     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2010-0234     Document Type: Article

References (20)

1. R.P. Schroeder,W.M. vanWeerden, C. Bangma, E.P.Krenning and M. de Jong, Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues, Methods 48(2) (Jun 2009), 200-204.
2. S.E. Pool, E.P. Krenning, G.A. Koning, C.H. van Eijck, J.J. Teunissen, B. Kam et al., Preclinical and clinical studies of peptide receptor radionuclide therapy, Semin Nucl Med 40(3) (May 2010), 209-218.
3. V. Tolmachev, S. Stone-Elander and A. Orlova, Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls, Lancet Oncol 11(10) (Oct 2010), 992-1000.
4. Q.T. Ho and C.J. Kuo, Vascular endothelial growth factor: biology and therapeutic applications, Int J Biochem Cell Biol 39(7-8) (2007), 1349-1357.
5. A.H. Varey, E.S. Rennel, Y. Qiu, H.S. Bevan, R.M. Perrin, S. Raffy et al., VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy, Br J Cancer 98(8) (22 Apr 2008), 1366-1379.
6. G. Korpanty, E. Smyth, L.A. Sullivan, R.A. Brekken and D.N. Carney, Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway, Exp Biol Med (Maywood) 235(1) (Jan 2010), 3-9.
7. M.S. Gordon, D.S.Mendelson and G. Kato, Tumor angiogenesis and novel antiangiogenic strategies, Int J Cancer 126(8) (15 Apr 2010), 1777-1787.
8. R.H. Alvarez, V. Valero and G.N. Hortobagyi, Emerging targeted therapies for breast cancer, J Clin Oncol 28(20) (10 Jul 2010), 3366-3379.
9. J.E. Park, G.A. Keller and N. Ferrara, The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF,Mol Biol Cell 4(12) (Dec 1993), 1317-1326.
10. T.H. Stollman, M.G. Scheer, G.M. Franssen, K.N. Verrijp, W.J. Oyen, T.J. Ruers et al., Tumor accumulation of radiolabeled bevacizumab due to targeting of celland matrixassociated VEGF-A isoforms, Cancer Biother Radiopharm 24(2) (Apr 2009), 195-200.
11. S.K. Chang, I. Rizvi, N. Solban and T. Hasan, In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment, Clin Cancer Res 14(13) (1 Jul 2008), 4146-4153.
12. I.M. Desar, A.B. Stillebroer, E. Oosterwijk, LeendersWP, van Herpen CM, van der Graaf WT et al., 111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib, J Nucl Med (18 Oct).
13. C.A. Boswell and M.W. Brechbiel, Development of radioimmunotherapeutic and diagnostic antibodies: an insideout view, Nucl Med Biol 34(7) (Oct 2007), 757-778.
14. M.W. Brechbiel, Bifunctional chelates for metal nuclides, Q J Nucl Med Mol Imaging 52(2) (Jun 2008), 166-173.
15. S.M. Abbas Rizvi, E.Y. Song, C. Raja, J. Beretov, A. Morgenstern, C. Apostolidis et al., Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth213 and Bismuth-205/ Bismuth-206, Cancer Biol Ther 7(10) (Oct 2008), 1547-1554.
16. L.G. Presta, H. Chen, S.J.O'Connor, V. Chisholm, Y.G.Meng, L. Krummen et al., Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res 57(20) (15 Oct 1997), 4593-4599.
17. Y.S. Ng, R. Rohan, M.E. Sunday, D.E. Demello and P.A. D'Amore, Differential expression ofVEGF isoforms inmouse during development and in the adult, Dev Dyn 220(2) (Feb 2001), 112-121.
18. W.B. Nagengast, E.G. de Vries, G.A. Hospers, N.H. Mulder, J.R. de Jong, H. Hollema et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft, J Nucl Med 48(8) (Aug 2007), 1313-1319.
19. T.H. Stollman,M.G. Scheer,W.P. Leenders,K.C.Verrijp, A.C. Soede, W.J. Oyen et al., Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody, Int J Cancer 122(10) (15 May 2008), 2310-2314.
20. M.G. Scheer, T.H. Stollman, O.C. Boerman, K. Verrijp, F.C. Sweep, W.P. Leenders et al., Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression, Eur J Cancer 44(13) (Sep 2008), 1835-1840.